Zur Rose Group AG

  • ISIN: CH0042615283
  • Land: Schweiz

Nachricht vom 16.11.2020 | 15:28

Zur Rose Group: gematik awards tender for specialist e-prescription service - Zur Rose subsidiary eHealth-Tec involved as partner to IBM

Zur Rose Group AG / Key word(s): Tender Offer

16-Nov-2020 / 15:28 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.


Ad hoc announcement

gematik awards tender for specialist e-prescription service - Zur Rose subsidiary eHealth-Tec involved as partner to IBM

eHealth-Tec GmbH, a German subsidiary of the Zur Rose Group of Switzerland, took part in the tender by gematik, the software service provider of the Federal Ministry of Health, for "provision of development services, computer centre infrastructure, system hardware and software as part of the launch of e-prescriptions" with IBM Deutschland GmbH as its partner. gematik today announced that IBM has won the tender for the specialist e-prescription service. eHealth-Tec is involved in the implementation as a partner to IBM. This includes providing the necessary infrastructure and operating and supporting the hardware and software components. The specialist e-prescription service has to be developed and designed to be able to process the entire volume of e-prescriptions issued in Germany and have scope for further expansion.

eHealth-Tec works as a technology provider in strategic partnerships with health insurers and others in the healthcare industry to successfully implement pilot e-prescription projects that are relevant to the market. eHealth-Tec contributed its accumulated experience as a systems provider for e-prescription solutions in the IBM submission. The successful participation in the gematik tender reinforces the role played by the Zur Rose Group as a pioneer in successfully introducing electronic prescriptions in Germany.

Investors and analyst contact
Christoph Herrmann, Head of Investor Relations
Email: ir@zurrose.com, phone: +41 58 810 11 49

Media contacts

Zur Rose Group:
Lisa Lüthi, Head of Group Communications
Email: media@zurrose.com, phone: +41 52 724 08 14

Segment Germany of the Zur Rose Group:
Torben Bonnke, Director Communication & PR
Email: torben.bonnke@docmorris.de, phone +49 30 21222 36 12

Agenda
21 January 2021 Sales 2020
18 March 2021 2020 Full-Year Results
20 April 2021 First Quarter Trading Update
29 April 2021 Annual General Meeting

Zur Rose Group

The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. It also operates the leading marketplace in southern Europe for consumer health, beauty and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany's best-known pharmacy brand DocMorris. Zur Rose employs more than 1,800 people at sites in Switzerland, Germany, the Netherlands, Spain and France. In 2019 it generated revenue of CHF 1,569 million (including medpex) and currently has around ten million active customers in core European markets.

With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care. It is also characterized by the continuous further development of digital services in the field of drug management using AI-supported applications and new technology. Zur Rose is furthermore actively driving ahead its positioning as a comprehensive provider of healthcare services. By creating a digital healthcare platform - the Zur Rose ecosystem - it networks products and digital services from qualified providers. The contribution made by Zur Rose will be to take these offerings to customers and patients and to make a relevant selection. The aim is to provide people with a seamless accompaniment and empower them to manage their own health optimally using products and digital solutions.

The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information please see zurrosegroup.com.



End of ad hoc announcement
Information and Explanation of the Issuer to this News:

Ad hoc announcement

gematik awards tender for specialist e-prescription service - Zur Rose subsidiary eHealth-Tec involved as partner to IBM

eHealth-Tec GmbH, a German subsidiary of the Zur Rose Group of Switzerland, took part in the tender by gematik, the software service provider of the Federal Ministry of Health, for 'provision of development services, computer centre infrastructure, system hardware and software as part of the launch of e-prescriptions' with IBM Deutschland GmbH as its partner. gematik today announced that IBM has won the tender for the specialist e-prescription service. eHealth-Tec is involved in the implementation as a partner to IBM. This includes providing the necessary infrastructure and operating and supporting the hardware and software components. The specialist e-prescription service has to be developed and designed to be able to process the entire volume of e-prescriptions issued in Germany and have scope for further expansion.

eHealth-Tec works as a technology provider in strategic partnerships with health insurers and others in the healthcare industry to successfully implement pilot e-prescription projects that are relevant to the market. eHealth-Tec contributed its accumulated experience as a systems provider for e-prescription solutions in the IBM submission. The successful participation in the gematik tender reinforces the role played by the Zur Rose Group as a pioneer in successfully introducing electronic prescriptions in Germany.

Investors and analyst contact
Christoph Herrmann, Head of Investor Relations
Email: ir@zurrose.com, phone: +41 58 810 11 49

Media contacts

Zur Rose Group:
Lisa Lüthi, Head of Group Communications
Email: media@zurrose.com, phone: +41 52 724 08 14

Segment Germany of the Zur Rose Group:
Torben Bonnke, Director Communication & PR
Email: torben.bonnke@docmorris.de, phone +49 30 21222 36 12

Agenda
21 January 2021 Sales 2020
18 March 2021 2020 Full-Year Results
20 April 2021 First Quarter Trading Update
29 April 2021 Annual General Meeting

Zur Rose Group

The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. It also operates the leading marketplace in southern Europe for consumer health, beauty and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany's best-known pharmacy brand DocMorris. Zur Rose employs more than 1,800 people at sites in Switzerland, Germany, the Netherlands, Spain and France. In 2019 it generated revenue of CHF 1,569 million (including medpex) and currently has around ten million active customers in core European markets.

With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care. It is also characterized by the continuous further development of digital services in the field of drug management using AI-supported applications and new technology. Zur Rose is furthermore actively driving ahead its positioning as a comprehensive provider of healthcare services. By creating a digital healthcare platform - the Zur Rose ecosystem - it networks products and digital services from qualified providers. The contribution made by Zur Rose will be to take these offerings to customers and patients and to make a relevant selection. The aim is to provide people with a seamless accompaniment and empower them to manage their own health optimally using products and digital solutions.

The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information please see zurrosegroup.com.




 

show this

Event im Fokus

Termine 2021

10. Juni 2021:Fachkonferenz Immobilien

14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure

13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie

10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix

„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“

GBC-Fokusbox

Cryptology Asset Group PLC: 120 % Kurspotenzial

GBC Research hat mit der Coverage der Cryptology Asset Group PLC (ISIN: MT0001770107) begonnen. Die Bewertung der führenden europäischen Investmentgesellschaft für Krypto-Assets und Blockchain-Unternehmen erfolgte mittels der Berechnung des Net Asset Value (NAV). Unter Berücksichtigung aller Beteiligungen ergibt sich zum 05. Juli 2021 eine GBC-Fair-NAV-Bewertung in Höhe von 1,04 Mrd. EUR. Daraus ergibt sich ein NAV je Cryptology-Aktie von 358,43 EUR. Daher empfiehlt GBC Research die Cryptology-Aktie zum Kauf und sieht ein Kurspotenzial von über 120 %.

News im Fokus

Delivery Hero startet globales Programm für nachhaltige Verpackungen zur Reduzierung von Plastikmüll

27. Juli 2021, 08:00

Aktueller Webcast

HENSOLDT AG

H1 2021 Analyst Call

04. August 2021

Aktuelle Research-Studie

Schweizer Electronic AG

Original-Research: Schweizer Electronic AG (von Montega AG): Halten

27. Juli 2021